文献速递膀胱癌与上尿路尿路上皮癌

转移性尿路上皮癌原发肿瘤部位手术的疗效:一项国际、多中心、多学科数据库分析

Efficacy of Surgery in the Primary Tumor Site for Metastatic Urothelial Cancer: Analysis of an International, Multicenter, Multidisciplinary Database.
PubMed 文献 · Eur Urol Oncol · 2019-07-13

这项多中心回顾性研究纳入2006年1月至2011年1月间接受一线铂类化疗的326例转移性尿路上皮癌患者,其中47例(14%)接受原发肿瘤部位手术。

要点

  • 326例转移性尿路上皮癌患者中47例(14%)接受原发肿瘤部位手术。
  • 手术与癌症特异性死亡(HR 0.59,p=0.04)和总死亡(HR 0.45,p=0.04)风险降低相关。
  • 手术的生存获益仅见于单一转移部位患者,两个及以上转移部位患者无获益。

核心结论

  • 原发肿瘤部位手术与接受标准化疗的转移性尿路上皮癌患者生存改善相关。
  • 该效应在两个及以上转移部位患者中消失。
  • 研究结果需在高品质前瞻性试验中验证。

研究设计与样本

  • 多中心协作的个体患者水平数据,纳入2006年1月至2011年1月间接受一线顺铂或卡铂为基础化疗的转移性尿路上皮癌患者,来自美国、欧洲、以色列和加拿大的医院。
  • 共纳入326例患者,其中47例(14%)接受原发肿瘤部位手术。
  • 采用单变量和多变量Cox回归分析,使用3个月界标分析评估手术对癌症特异性死亡和总死亡的影响。

主要发现

  • 中位随访43个月(四分位距33-45个月)。
  • 接受手术的患者中,28例(60%)为原发性膀胱癌,19例(40%)为原发性上尿路肿瘤。
  • 仅纳入化疗开始前接受手术的患者时,结果相似。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 研究为回顾性性质。
  • 研究结果需在高品质前瞻性试验中验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The effect of local treatment on survival in advanced-stage patients has gained interest in several malignancies; however, limited data exist regarding urothelial carcinoma (UC). OBJECTIVE: To test the impact of surgery of the primary tumor site on cancer-specific mortality (CSM) and overall mortality (OM) in patients affected by metastatic UC. DESIGN, SETTING, AND PARTICIPANTS: Individual patient-level data from a multicenter collaboration, including metastatic UC patients treated with first-line cisplatin- or carboplatin-based chemotherapy administered between January 2006 and January 2011 from hospitals in the USA, Europe, Israel, and Canada. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Univariable and multivariable Cox regression analyses were used to assess the effect of surgery on CSM and OM in patients affected by metastatic UC using 3-mo landmark analyses. Subgroup analyses were performed on the basis of the number of metastasis sites involved and including only patients treated with surgery before the start of chemotherapy. RESULTS AND LIMITATIONS: Of the 326 patients included in the study, 47 (14%) were treated with surgery of the primary tumor site. Median (interquartile range) follow-up was 43 (33-45)mo. Of the patients treated with surgery, 28 (60%) were affected by a primary bladder cancer and 19 (40%) by a primary upper urinary tract tumor. On multivariable analyses, surgery was associated with a protective effect on CSM (hazard ratio [HR]: 0.59, confidence interval [CI]: 0.35-0.98, p=0.04) and OM (HR: 0.45, CI: 0.37-0.99, p=0.04) compared with patients treated with chemotherapy only. Similar results were found considering patients only surgically treated before the start of chemotherapy. After stratifying according to the number of metastatic sites, surgery has an effect on survival in patients with only one metastatic site, while no survival benefit was observed in patients with two or more metastatic sites. The study is limited by its retrospective nature. CONCLUSIONS: We found that surgery of the primary tumor site is associated with improved survival in patients with metastatic UC who received standard chemotherapy. This effect disappears in patients affected by two or more metastatic sites. Our results need to be validated in a high-quality prospective trial. PATIENT SUMMARY: In our multicenter, retrospective series, surgery in metastatic urothelial cancer patients improve survival compared with patients treated with chemotherapy only. This effect was evident in patients with limited disease extent, identified as one metastatic site.

来源:Eur Urol Oncol,查看原文。版权归原作者所有。

引用

  1. Moschini M, Xylinas E, Zamboni S, et al. Efficacy of Surgery in the Primary Tumor Site for Metastatic Urothelial Cancer: Analysis of an International, Multicenter, Multidisciplinary Database. Eur Urol Oncol. 2019. PMID: 31307962. doi:10.1016/j.euo.2019.06.014

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。